Company Insight – Page 25 – media

Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
- Source: finance.yahoo
- 415
- November 17, 2017
Company Insight Hunter syndrome MPS II
Novartis posts eye drug data amid play for Eylea’s turf

Novartis’s bid to move in on Bayer’s and Regeneron’s eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker’s new RTH258 drug showed less disease activity than those on its rivals’ drug Eylea.
- Source: reuters
- 440
- November 13, 2017
active disease AMD Company Insight RTH258
Medical startup raises £15m for augmented reality surgery headsets

London startup developing holographic surgery headsets has raised $20m (£15m) from the backers of Facebook’s Oculus headset.
- Source: telegraph
- 542
- November 9, 2017
Company Insight surgery headset
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 487
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Merck subsidiary StayWell acquires app maker MedHelp for undisclosed sum

To expedite its push into mobile health, Yardley, Pennsylvania-based StayWell announced today that it has acquired the mobile health portion of Silicon Valley-based MedHelp, which includes several consumer-facing mobile health apps.
- Source: mobihealthnews
- 495
- November 6, 2017
Company Insight health apps MedHelp Merck
CVS-Aetna deal won’t necessarily make drugs cheaper — and could even raise prices

CVS Health Corp.’s bid for Aetna Inc., which could be valued at more than $66 billion, would — if successful — combine two businesses that have traditionally been separate, health insurance and pharmacy-benefit management.
- Source: marketwatch
- 431
- October 31, 2017
Company Insight CVS drug pharmacy
CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
- Source: Pmlive
- 922
- October 30, 2017
Company Insight HIV Shingrix Tivicay Triumeq vaccine
Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome

Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment.
- Source: reuters
- 818
- October 23, 2017
ADA-SCID Company Insight gene Market Views NICE
Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

Takeda Pharmaceutical Company Limited and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).
- Source: finance.yahoo
- 442
- October 18, 2017
Company Insight NASH therapeutics
Neurotech International bags $4M to commercialise autism device

Neurotech International Ltd has successfully raised $4 million via a placement of shares at $0.20 each to drive its ongoing commercialisation of the Mente Autism device.
- Source: proactiveinvestors
- 666
- October 18, 2017
ASD autism Company Insight EEG medical device

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.